THOR Industries Announces Fourth Quarter and Fiscal 2023 Results
Fourth Quarter Results Underscore Continued Strong European Segment Performance and Solid Execution Within North American Down-Cycle as Company Remains Focused...
Read moreDetails
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Archer Aviation, Inc. of Class Action Lawsuit and Upcoming Deadline – ACHR
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against...
Read moreDetailsFDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD...
Read moreDetailsnCino to Host Inaugural Investor Day
WILMINGTON, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ:NCNO), a pioneer in cloud banking for the global financial...
Read moreDetailsGain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the...
Read moreDetailsPliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced it will host...
Read moreDetailsGreat Lakes Announces Participation in Noble Capital Markets C-Suite Interview Series
HOUSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD),...
Read moreDetailsSocietal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference
SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL),...
Read moreDetailsLocanabio Announces Participation in Chardan’s 7th Annual Genetic Medicines Conference
SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with...
Read moreDetailsOmega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
Read moreDetailsADVERTISEMENTS
